
    
      In EASTYLE trial, the investigators aim to evaluate the efficacy and safety of de-escalation
      strategy ticagrelor (60/45 mg twice daily), as compared with standard strategy ticagrelor (90
      mg twice daily) in East Asian patients with AMI undergoing PCI.

      All eligible AMI patients receive loading dose of ticagrelor 180 mg plus aspirin 300 mg,
      following ticagrelor 90 mg twice daily plus aspirin 100 mg daily during the index
      hospitalization. Subsequently, to be randomly assigned into ticagrelor 90 mg and ticagrelor
      60/45 mg twice daily in combination with aspirin 100 mg daily at discharge for at least
      12-month period treatment.

      The investigators focusing on the efficacy and safety endpoint, is net adverse clinical and
      cerebrovascular events (NACCE), composite of all-cause mortality, myocardial infarction,
      stroke, and major bleeding.
    
  